| Year |
Citation |
Score |
| 2015 |
Harrington KH, Gudgeon CJ, Laszlo GS, Newhall KJ, Sinclair AM, Frankel SR, Kischel R, Chen G, Walter RB. The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk. Plos One. 10: e0135945. PMID 26305211 DOI: 10.1371/Journal.Pone.0135945 |
0.337 |
|
| 2014 |
Laszlo GS, Gudgeon CJ, Harrington KH, Dell'Aringa J, Newhall KJ, Means GD, Sinclair AM, Kischel R, Frankel SR, Walter RB. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. Blood. 123: 554-61. PMID 24311721 DOI: 10.1182/Blood-2013-09-527044 |
0.325 |
|
| 2014 |
Krupka C, Brauneck F, Lichtenegger FS, Kufer P, Kischel R, Zugmaier G, Köhnke T, Altmann T, Schneider S, Fiegl M, Spiekermann K, Sinclair AM, Newhall KJ, Frankel SR, Baeuerle P, et al. Hydroxyurea Is Most Suitable for Cytoreduction of AML Prior to CD33/CD3 Bispecific BiTE® Antibody (AMG 330) Therapy: Uncompromised T-Cell Proliferation Ex-Vivo and CD33 Upregulation on AML Cells Blood. 124: 986-986. DOI: 10.1182/Blood.V124.21.986.986 |
0.33 |
|
| 2014 |
Harrington KH, Gudgeon CJ, Laszlo GS, Newhall KJ, Sinclair AM, Frankel SR, Kischel R, Chen G, Walter RB. The Broad Activity of the CD33/CD3 Bispecific BiTE® Antibody AMG 330 in Primary Human AML Is Impacted By Disease Stage and Cytogenetic/Molecular Risk Blood. 124: 266-266. DOI: 10.1182/Blood.V124.21.266.266 |
0.343 |
|
| 2005 |
Newhall KJ, Cummings DE, Nolan MA, McKnight GS. Deletion of the RIIbeta-subunit of protein kinase A decreases body weight and increases energy expenditure in the obese, leptin-deficient ob/ob mouse. Molecular Endocrinology (Baltimore, Md.). 19: 982-91. PMID 15618289 DOI: 10.1210/Me.2004-0343 |
0.393 |
|
| Show low-probability matches. |